Venlo, the Netherlands, Oct. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023.
Press release date / time: Monday, October 30, shortly after 21:05 Frankfurt time / 20:05 London time / 16:05 New York time. (For Europe: Due to the U.S. time switch, our Press release will be published one hour earlier than usual.)
Conference call date / time: Tuesday, October 31, at 14:00 Frankfurt time / 13:00 London time / 09:00 New York time.
(For Europe: Due to the U.S. time switch, our conference call will be held one hour earlier than usual.)
Three options for joining the conference call
Service available 15 minutes before call start
U.S.: +1 646 828 8193
UK: +44 (0)330 165 3656
GER: +49 (0)69 6610 2491
Conference ID: 4759185
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.
A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/event_security_fail.html
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2023, QIAGEN employed more than 6,100 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Last Trade: | US$44.05 |
Daily Change: | -1.29 -2.85 |
Daily Volume: | 795,083 |
Market Cap: | US$9.790B |
December 12, 2024 November 28, 2024 November 27, 2024 November 06, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB